The AbbVie/Alvotech debacle on a Humira biosimilar has taken yet another turn — escalating tensions between the two biotechs. The pharma giant filed a complaint with the US International Trade…
Moderna has backed down on its patent fight with the NIH, calling a truce by dropping its patent application for now. Following a heated feud regarding who invented its lifesaving Covid-19 vaccine…
With a jam-packed pipeline to parse, Novartis chief Vas Narasimhan has helped investors out in the past by highlighting a few key programs his team thinks could be easy winners. One of those drugs has…
About a year after Geneva-based Chord Therapeutics emerged from stealth to see if it could repurpose an old chemotherapy agent for rare diseases, Merck KGaA is swooping in with a buyout. While the…
Omid Farokhzad didn’t have to travel far to find a private biotech he wanted to take public with his $200 million blank-check company. Senti Bio — the synthetic biology play launched and now helmed by…
In a lucrative market for ocular degeneration, Roche has long sat on a gold mine with its drug Lucentis — but the times are changing. Now, Roche will bet on a regenerative approach to eye disease with…
After last year’s Phase III results, there was little question that the FDA would approve Amgen and AstraZeneca’s long-incubating antibody for asthma, barring any manufacturing delays or shocking…
Sen. Joe Manchin on Sunday derailed President Biden’s trillion-dollar spending package, effectively halting the Democrats’ best chance yet to allow Medicare to negotiate drug prices, among a bevy of…
Drug pricing reform has been a political football for years, with both Donald Trump and Joe Biden championing changes during their presidencies. Little has moved the needle on Capitol Hill, however,…
Bluebird bio has been hit with another hold on one of its gene therapy programs. The company announced Monday that the FDA had placed a partial hold on its sickle cell gene therapy trials for children…
